Once-weekly semaglutide shows significant reduction in knee osteoarthritis pain and body weight in adults with obesity, a ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Semaglutide, the active ingredient in Ozempic, has shown promising results in weight loss and blood sugar management. But did ...

The position was supported by the TRAVERSE trial findings. (Mayo Clinic Proceedings) All doses of semaglutide (Ozempic, ...

Wegovy® is the only version of semaglutide that is FDA-approved for weight loss, while Ozempic® and other forms of the drug ...

Novo Nordisk’s CEO has alerted healthcare professionals about the growing risks associated with compounded semaglutide, a ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

“Patients who believe that they’re getting access to a safe product, and they believe they’re getting semaglutide … I know ...

Ozempic and Wegovy, made by Novo Nordisk, are now listed as available across all doses on the FDA’s drug shortage list. But ...

For years, scientists have observed a connection between type 2 diabetes and an increased risk of dementia, particularly ...

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

A retrospective cohort study using data from patients in 21 countries showed use of semaglutide use was not linked to an ...